MX2022004588A - Método para producir anticuerpo marcado con metal radioactivo. - Google Patents

Método para producir anticuerpo marcado con metal radioactivo.

Info

Publication number
MX2022004588A
MX2022004588A MX2022004588A MX2022004588A MX2022004588A MX 2022004588 A MX2022004588 A MX 2022004588A MX 2022004588 A MX2022004588 A MX 2022004588A MX 2022004588 A MX2022004588 A MX 2022004588A MX 2022004588 A MX2022004588 A MX 2022004588A
Authority
MX
Mexico
Prior art keywords
radioactive metal
atomic group
labeled antibody
producing radioactive
peptide
Prior art date
Application number
MX2022004588A
Other languages
English (en)
Inventor
Hiroaki Ichikawa
Akihiro Izawa
Yuki Okumura
Yu Ogawa
Minoru KAWATANI
Hideaki Takemori
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of MX2022004588A publication Critical patent/MX2022004588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

El método de producción de un anticuerpo marcado con metal radioactivo de la presente invención incluye un paso de realizar una reacción de clic de un complejo de metal radioactivo y un anticuerpo modificado específicamente en el sitio con un péptido para producir un anticuerpo marcado con metal radioactivo; la reacción de clic se realiza entre un primer grupo atómico del complejo de metal radioactivo y un segundo grupo atómico ligado directamente o indirectamente al péptido; el segundo grupo atómico es un grupo atómico que contiene un grupo azida o un grupo atómico que contiene transcicloocteno.
MX2022004588A 2019-10-18 2020-10-16 Método para producir anticuerpo marcado con metal radioactivo. MX2022004588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019191561 2019-10-18
PCT/JP2020/039076 WO2021075546A1 (ja) 2019-10-18 2020-10-16 放射性金属標識抗体の製造方法

Publications (1)

Publication Number Publication Date
MX2022004588A true MX2022004588A (es) 2022-07-21

Family

ID=75538111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004588A MX2022004588A (es) 2019-10-18 2020-10-16 Método para producir anticuerpo marcado con metal radioactivo.

Country Status (13)

Country Link
US (1) US20230248854A1 (es)
EP (1) EP4047010A4 (es)
JP (1) JPWO2021075546A1 (es)
KR (1) KR20220083768A (es)
CN (1) CN114555132A (es)
AU (1) AU2020367624A1 (es)
BR (1) BR112022007240A2 (es)
CA (1) CA3158344A1 (es)
IL (1) IL292312A (es)
MX (1) MX2022004588A (es)
TW (1) TW202128732A (es)
WO (1) WO2021075546A1 (es)
ZA (1) ZA202205154B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230088764A (ko) * 2020-10-16 2023-06-20 니혼 메디피직스 가부시키가이샤 항her2 항체의 방사성 복합체, 및 방사성 의약
JP7154465B1 (ja) 2021-01-08 2022-10-17 日本メジフィジックス株式会社 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法
WO2022224980A1 (ja) * 2021-04-20 2022-10-27 日本メジフィジックス株式会社 抗ｃｄ２０抗体の放射性複合体、及び、放射性医薬
TW202325343A (zh) * 2021-08-31 2023-07-01 日商日本醫事物理股份有限公司 去醣基化抗體之放射性複合體，及放射性醫藥
WO2023190402A1 (ja) * 2022-03-30 2023-10-05 日本メジフィジックス株式会社 複合体の製造方法
WO2024108304A1 (en) * 2022-11-23 2024-05-30 Standard Biotools Canada Inc. Dithiol chelators for metal conjugation to antibodies
CN117466980A (zh) * 2023-11-02 2024-01-30 浙江普罗亭健康科技有限公司 基于多肽链骨架应用于金属抗体标记的负载金属缀合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3160513T3 (da) * 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
WO2016186206A1 (ja) 2015-05-20 2016-11-24 国立大学法人鹿児島大学 ＩｇＧ結合ペプチドによる抗体の特異的修飾
JP6959616B2 (ja) 2016-06-13 2021-11-02 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチドによる部位特異的ＲＩ標識抗体
JP7291395B2 (ja) 2017-06-16 2023-06-15 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
AU2018388467A1 (en) 2017-12-18 2020-06-11 Janssen Biotech, Inc. Radiolabeling of polypeptides
KR20200143366A (ko) * 2018-04-16 2020-12-23 니혼 메디피직스 가부시키가이샤 수식 항체 및 방사성 금속 표지 항체

Also Published As

Publication number Publication date
IL292312A (en) 2022-06-01
CA3158344A1 (en) 2021-04-22
EP4047010A4 (en) 2024-01-10
WO2021075546A1 (ja) 2021-04-22
TW202128732A (zh) 2021-08-01
BR112022007240A2 (pt) 2022-07-05
AU2020367624A1 (en) 2022-05-19
ZA202205154B (en) 2023-11-29
US20230248854A1 (en) 2023-08-10
KR20220083768A (ko) 2022-06-20
CN114555132A (zh) 2022-05-27
EP4047010A1 (en) 2022-08-24
JPWO2021075546A1 (es) 2021-04-22

Similar Documents

Publication Publication Date Title
ZA202205154B (en) Method for producing radioactive metal-labeled antibody
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
MX2010001488A (es) Composiciones y metodos para cristalizar anticuerpos.
MX2022011780A (es) Composiciones que contienen anticuerpos activables.
MY179409A (en) Method for producing ?-caprolactam
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
MX2022007798A (es) Metodo de produccion de conjugado de anticuerpo-farmaco a base de eribulina.
Yang et al. Higgs couplings and Naturalness in the littlest Higgs model with T-parity at the LHC and TLEP
WO2018167141A3 (en) Target detection using a monovalent antibody
AU2002951409A0 (en) Methods for regulating cancer
Kao et al. Synthetic nanobodies as tools to distinguish IgG Fc glycoforms
ATE217888T1 (de) Monoklonale antikörper gegen leukozyten- spezifische g-protein-gekoppelte rezeptoren
Vanuzzo et al. Reaction N (2D)+ CH2CCH2 (Allene): an experimental and theoretical investigation and implications for the photochemical models of Titan
MX2022014420A (es) Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos.
Choi et al. Higgs phenomenology in the Peccei-Quinn invariant NMSSM
WO2019239330A3 (en) Intricate mixed-linker structures
MX2021003407A (es) Cuantificacion de anticuerpos en muestras biologicas.
MX2022002324A (es) Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos.
MX2022002110A (es) Optimizacion de formulacion para anticuerpos bisespecificos.
MY180272A (en) A monoclonal antibody inhibiting immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody
MX2020008630A (es) Lamina de acero de alta resistencia, lamina de acero galvanizado de alta resistencia, metodo para producir lamina de acero de alta resistencia y metodo para producir lamina de acero galvanizado de alta resistencia.
WO2020127354A3 (en) Polypeptides
WO2019099454A3 (en) Highly functional antibody libraries
Thornton et al. High-frequency in situ δ 13 C-CH 4 and δD-CH 4 observations from Zeppelin Mountain, Svalbard
CL2022002920A1 (es) Proceso de producción de nitrato de amonio